Novartis reports a strong launch for its one-shot gene therapy Zolgensma—the world’s most expensive drug—which promises to cure a devastating muscle-wasting disease in infants https://t.co/0KApvK84gD — The Wall Street Journal (@WSJ) October 22, 2019
Novartis reports a strong launch for its one-shot gene therapy Zolgensma—the world’s most expensive drug—which promises to cure a devastating muscle-wasting disease in infants https://t.co/0KApvK84gD